Current and Future Directions for PARP Inhibition
Presented by Megan Grudem, APRN, CNP, and Andrea Wahner Hendrickson, MD
From Mayo Clinic, Rochester, Minnesota
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2020;11(3):297–300 |
© 2020 Harborside™
Megan Grudem, APRN, CNP, and Andrea Wahner Hendrickson, MD, reviewed the potential role of PARP inhibition in various malignancies, how to select patients who are appropriate candidates, and guidance on devising treatment plans that include PARP inhibitors for patients with ovarian or breast cancer based on genetic profiles, tolerability, dosing schedules, and other key factors.
For access to the full length article, please sign in